Development and validation of a clinical model to predict the presence of β-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients

Clinical Infectious Diseases

Volumn 59, Issue 2, 2014, Pages 223-230

  Shelburne, Samuel A ^a   Lasky, Robert E ^b   Sahasrabhojane, Pranoti ^a   Tarrand, Jeffrey T ^a   Rolston, Kenneth V I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

clinical model

Indexed keywords

BETA LACTAM; CEFEPIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; DAPTOMYCIN; GATIFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CANCER PATIENT; CATHETER INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOMA; NEUTROPHIL COUNT; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SEPTIC SHOCK; SOFT TISSUE INFECTION; SOLID TUMOR; TREATMENT DURATION; VALIDATION STUDY; AGED; COHORT ANALYSIS; COMPLICATION; DECISION SUPPORT SYSTEM; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEOPLASM; NEUTROPENIA; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STREPTOCOCCUS INFECTION;

ADULT; AGED; BACTEREMIA; BETA-LACTAM RESISTANCE; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STREPTOCOCCAL INFECTIONS; VIRIDANS STREPTOCOCCI;

EID: 84904023132     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu260     Document Type: Article

References (32)

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52:e56-93.
2. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: Pros and cons. Clin Infect Dis. 1999; 29:503-7. (Pubitemid 29439942)
3. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against gram-positive infections for febrile neutropenia: Systematic review and meta-Analysis of randomized controlled trials. J Antimicrob Chemother 2005; 55:436-44. (Pubitemid 40542581)
4. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988; 319:1053-8.
5. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988; 108:30-5. (Pubitemid 18081166)
6. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25:247-59. (Pubitemid 27364722)
7. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002; 34:1524-9. (Pubitemid 34553713)
8. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors. Clin Infect Dis. 1992; 14:1201-7.
9. Marron A, Carratala J, Gonzalez-Barca E, Fernandez-Sevilla A, Alcaide F, Gudiol F. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis. 2000; 31:1126-30. (Pubitemid 32295438)
10. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin Infect Dis. 1994; 18:25-31. (Pubitemid 24025915)
11. Dix D, Cellot S, Price V, et al. Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): Results from the Canadian infections in AML research group. Clin Infect Dis. 2012; 55:1608-14.
12. Arns da Cunha C, Weisdorf D, Shu XO, DeFor T, Pastor JD 3rd, Johnson JR. Early gram-positive bacteremia in BMT recipients: Impact of three different approaches to antimicrobial prophylaxis. Bone Marrow Transplant 1998; 21:173-80. (Pubitemid 28044011)
13. Jaffe D, Jakubowski A, Sepkowitz K, et al. Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: A single-center observational cohort study. Clin Infect Dis. 2004; 39:1625-32. (Pubitemid 39578536)
14. Cattaneo C, Casari S, Bracchi F, et al. Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis. 2010; 42:324-32.
15. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342:710-21. (Pubitemid 30131425)
16. Schots R, Trullemans F, Van Riet I, et al. The clinical impact of early gram-positive bacteremia and the use of vancomycin after allogeneic bone marrow transplantation. Transplantation 2000; 69:1511-4. (Pubitemid 30238752)
17. Hughes WT, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990; 161:381-96. (Pubitemid 20107933)
18. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997; 25:551-73. (Pubitemid 127774275)
19. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34:730-51. (Pubitemid 34194843)
20. Paulus S, Dobson S, Rassekh S, Blondel-Hill E. In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: Implications for antibiotic choices. J Pediatr Hematol Oncol 2009; 31:267-9.
21. Alcaide F, Linares J, Pallares R, et al. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995; 39:2243-7.
22. Nucci M, Landau M, Silveira F, Spector N, Pulcheri W. Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: Impact on reducing the use of glycopeptides. Infect Control Hosp Epidemiol 2001; 22:651-3. (Pubitemid 33152111)
23. Carratala J, Alcaide F, Fernandez-Sevilla A, Corbella X, Linares J, Gudiol F. Bacteremia due to viridans streptococci that are highly resistant to penicillin: Increase among neutropenic patients with cancer. Clin Infect Dis. 1995; 20:1169-73.
24. Spanik S, Trupl J, Kunova A, et al. Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: Analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis. Scand J Infect Dis. 1997; 29:245-9.
25. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009; 136:e28.
26. Spellerberg B, Brandt C. Streptococcus. In: Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D, eds. Manual of clinical microbiology. Vol 1. Washington, DC: ASM Press, 2011:341-9.
27. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th informational supplement M100-S20. Wayne, PA: CLSI, 2010.
28. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44:837-45.
29. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, 2013. Available at: Http://www.eucast.org. Accessed 15 October 2013.
30. Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Additional anti-gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev. 2005; CD003914.
31. Low DE, de Azavedo J, Davidson R. In vitro activity of cefepime against multidrug-resistant gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study. Can J Infect Dis. 1999; 10:122-7. (Pubitemid 29239045)
32. Marron A, Carratala J, Alcaide F, Fernandez-Sevilla A, Gudiol F. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother 2001; 47:87-91. (Pubitemid 32058760)